Eli Lilly joins Illumina’s Billion Cell Atlas alliance aimed at expanding AI drug-discovery datasets

Eli Lilly is becoming a foundational participant in Illumina’s Billion Cell Atlas alliance, a multi-company effort focused on building what is described as a genome-wide genetic perturbation dataset at very large scale. The announcement, carried by Yahoo Finance, frames the dataset as a core input for AI-driven drug discovery, where researchers aim to connect genes to biological effects in ways that can accelerate target identification and early hypothesis testing.

Genetic perturbation datasets map how specific genetic changes alter cellular behavior. In this case, the alliance is described as working toward a genome-wide genetic perturbation resource that can be used to observe outcomes across many genetic modifications. Illumina and participating organizations have characterized the goal as building the world’s largest such dataset, with the scale intended to improve the training material for machine-learning models and to support more robust predictions about which biological pathways may be relevant to disease.

Lilly’s role is described in the report as joining the alliance as a “foundational participant.” While the Yahoo Finance post does not spell out Lilly’s specific contributions or timelines, the phrasing suggests the company is stepping in at the early stage of the program rather than as a later add-on partner. For a large pharmaceutical company, that type of early participation can matter because data-generation standards, access terms, and downstream collaboration frameworks can shape how useful the dataset becomes for internal discovery programs.

The Billion Cell Atlas alliance is presented as an “AI drug discovery” initiative, reflecting a broader shift in the industry toward using data-intensive models to reduce the cost and time associated with early discovery. In practical terms, Lilly and other participants would be looking to use the atlas data to improve the quality of model inputs, and to generate or test predictions about gene targets and mechanisms. The report does not indicate whether Lilly plans to apply the atlas outcomes to specific therapeutic areas, but it places the collaboration firmly in the discovery workflow rather than late-stage clinical development.

Illumina’s business is closely tied to sequencing and other genomic technologies, and its alliance-building efforts generally aim to expand the ecosystem of datasets and analytical methods built on top of those platforms. For Illumina, bringing major pharmaceutical partners into the atlas work can help ensure that the data and annotation approaches align with how discovery groups actually use genomic and functional information.

Still, the publicly described information leaves multiple questions unanswered. The Yahoo Finance post does not provide details on what data Lilly will generate or contribute, whether Lilly will have preferential access to specific elements of the atlas, or how the alliance will handle intellectual property and commercialization rights tied to any resulting models or therapeutic candidates. It also does not disclose a program budget, expected completion dates, or quantitative milestones for dataset size beyond the “world’s largest” characterization.